Výsledky vyhledávání - "Christopher Enny"

Akademický článek

WORKING CAPITAL MANAGEMENT AND FINANCIAL PERFORMANCE: EVIDENCE FROM ALTERNATIVE ENERGY FIRMS IN THE UK.

Autor: Ebire, Kolawole, Onmonya, Lucky Otsoge, Ofikwu, Christopher Enny, Adegbenro, Deborah Fadekemi

Publikováno v: International Journal of Professional Business Review (JPBReview); 2024, Vol. 9 Issue 4, p1-21, 21p

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Autor: Olga Samoilova, Christopher Enny, João Raposo, Viacheslav Pavlov, Deborah Ricci, Hyeon-Seok Eom, Aleksandra Rizo, Eugene Zhu, Burhan Ferhanoglu, Max S. Topp, Shalini Chaturvedi, Fritz Offner, Osmanov Ea, Helgi van de Velde

Publikováno v: Blood. 126:1893-1901

This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse lar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f283e646d363aae97d3cc8d45853d40
https://doi.org/10.1182/blood-2015-03-632430

Zobrazit plný text záznamu

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

Autor: Anna Dmoszynska, Deborah Ricci, Ivan Spicka, Don Robinson, Christopher Enny, Richard Greil, Ofer Shpilberg, Bruno Paiva, Jean Luc Harousseau, María Belén Vidriales, Tamas Masszi, Andrew Cakana, Anne-Marie Stoppa, Luisa Viterbo, Graça Esteves, Helgi van de Velde, Huaibao Feng, Roman Hájek, Heinz Ludwig

Publikováno v: Journal of Clinical Oncology. 31:247-255

Purpose Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM). This phase II, noncomparative study sought to determine whether addition of cyclophosphamide to this regimen (VTDC) could further increase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5006913f24dafd19b82562ed66448705
https://doi.org/10.1200/jco.2011.39.5137

Zobrazit plný text záznamu

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Autor: Dixie Lee Esseltine, Vaishali Sanchorawala, Giampaolo Merlini, Andrew Cakana, Leonard T. Heffner, Donna E. Reece, Jean Paul Fermand, Joan Bladé, Hani Hassoun, Helgi van de Velde, Ute Hegenbart, Raymond L. Comenzo, Kevin Liu, Robert Vescio, Giovanni Palladini, Christopher Enny

Publikováno v: Blood. 118:865-873

This first prospective phase 2 study of single-agent bortezomib in relapsed primary systemic AL amyloidosis evaluated the recommended (maximum planned) doses identified in phase 1 testing (1.6 mg/m2 once weekly [days 1, 8, 15, and 22; 35-day cycles];

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e7b74196c34875537bc8cc7bc0e7f54
https://doi.org/10.1182/blood-2011-02-334227

Zobrazit plný text záznamu

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

Autor: Simon W Dubrey, Robert Vescio, Joan Bladé, Xiangyang Liu, Raymond L. Comenzo, Hani Hassoun, Yusri Elsayed, Andrew Cakana, Giovanni Palladini, Giampaolo Merlini, Donna E. Reece, Vaishali Sanchorawala, S. Mortimer, Leonard T. Heffner, Ute Hegenbart, Christopher Enny, P. Ramaswami, Jean Paul Fermand, H van de Velde

Publikováno v: QJM. 104:957-970

Background: Bortezomib is approved for the treatment of multiple myeloma and a role has been suggested in the treatment of systemic AL amyloidosis (AL). Methods: In this phase 1 dose-escalation portion of the first prospective study of single-agent b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7551092e52bd96d37d9c61bb398c9d
https://doi.org/10.1093/qjmed/hcr105

Zobrazit plný text záznamu

Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin

Autor: Ernest F. J. Block, Timothy C. Fabian, Lena M. Napolitano, Christopher Enny, Jeffrey A. Bailey, Howard L. Corwin, Kathleen Kelly, Wayne Langholff

Publikováno v: Journal of Trauma: Injury, Infection & Critical Care. 65:285-299

Background: A randomized, double-blind, placebo-controlled, multicenter trial (EPO-2, N = 1,302) in anemic critically ill patients demonstrated a 29-day survival benefit in the trauma subgroup receiving epoetin alfa (mortality 8.9% vs. 4.1%). A secon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f6bd45b4c5e705ae4936c0ce1544cc9
https://doi.org/10.1097/ta.0b013e31817f2c6e

Zobrazit plný text záznamu

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Autor: Anne-Marie Stoppa, Tamas Masszi, Ofer Shpilberg, Shalini Chaturvedi, Don Robinson, Graça Esteves, Bruno Paiva, Helgi van de Velde, Anna Dmoszynska, Roman Hájek, María Belén Vidriales, Richard Greil, Ozlem Ataman, Heinz Ludwig, Huaibao Feng, Christopher Enny, Luisa Viterbo, Ivan Spicka

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
British Journal of Haematology

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License.-- et al.
This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8193c8c6c2d17ccca8f54704b0bb256c
http://hdl.handle.net/10261/134835

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání